{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T07:45:35Z","timestamp":1784447135650,"version":"3.55.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T00:00:00Z","timestamp":1761350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>This review aims to provide an updated overview of the clinical management of heart failure and comorbidities in transthyretin amyloid cardiomyopathy (ATTR-CM). We sought to address key unanswered questions and current uncertainties regarding treatment response, prognosis, and optimization of care in this complex population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Once considered rare, ATTR-CM is now increasingly recognized due to greater awareness and the possibility of non-invasive diagnosis. Patients are often identified at earlier stages, with lower mortality than historically observed. Disease-modifying therapies with proven efficacy in randomized trials are now available, yet many patients experience disease progression. In real-world practice, ATTR-CM patients are typically older and have multiple cardiac and extracardiac comorbidities, often representing exclusion criteria of clinical trials, which may influence treatment response and efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Modern management of ATTR-CM should integrate heart failure treatment with tailored approaches to comorbidity care. Earlier diagnosis, real-world evidence, and strategies for patients outside trial populations will be essential to improve prognosis and guide future research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11886-025-02308-6","type":"journal-article","created":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T13:42:39Z","timestamp":1761399759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Weight of Comorbidities in the Specific Treatment of ATTR-Related Amyloid Cardiomyopathy"],"prefix":"10.1007","volume":"27","author":[{"given":"Anna","family":"Cantone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Maria","family":"Dicorato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldostefano","family":"Porcari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,25]]},"reference":[{"issue":"18","key":"2308_CR1","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","volume":"118","author":"A Porcari","year":"2023","unstructured":"Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. Cardiovasc Res. 2023;118(18):3517\u201335.","journal-title":"Cardiovasc Res"},{"issue":"7","key":"2308_CR2","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34(7):520\u20138.","journal-title":"Eur Heart J"},{"issue":"24","key":"2308_CR3","first-page":"2404","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis Cardiac Transthyretin Amyloidosis Circulation. 2016;133(24):2404\u201312.","journal-title":"Nonbiopsy Diagnosis Cardiac Transthyretin Amyloidosis Circulation"},{"issue":"5","key":"2308_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jamacardio.2024.5221","volume":"10","author":"A Porcari","year":"2025","unstructured":"Porcari A, Razvi Y, Cappelli F, Nitsche C, Serenelli M, Longhi S, et al. Clinical phenotype and prognosis of asymptomatic patients with transthyretin cardiac amyloid infiltration. JAMA Cardiol. 2025;10(5):437.","journal-title":"JAMA Cardiol"},{"issue":"10","key":"2308_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","volume":"19","author":"A Aimo","year":"2022","unstructured":"Aimo A, Castiglione V, Rapezzi C, Franzini M, Panichella G, Vergaro G, et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat Rev Cardiol. 2022;19(10):655\u201367.","journal-title":"Nat Rev Cardiol"},{"key":"2308_CR6","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-3-031-51757-0_21","volume-title":"Treatment of ATTR amyloidosis: from stabilizers to gene editing BT - Cardiac amyloidosis: diagnosis and treatment","author":"A Porcari","year":"2024","unstructured":"Porcari A, Maurer MS, Gillmore JD. In: Emdin M, Vergaro G, Aimo A, Fontana M, editors. Treatment of ATTR amyloidosis: from stabilizers to gene editing BT - Cardiac amyloidosis: diagnosis and treatment. Cham: Springer Nature Switzerland; 2024. pp. 261\u201378."},{"issue":"1","key":"2308_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.17925\/HI.2024.18.1.5","volume":"18","author":"A Ioannou","year":"2024","unstructured":"Ioannou A. Evolution of disease-modifying therapy for transthyretin cardiac amyloidosis. Heart Int. 2024;18(1):30\u20137.","journal-title":"Heart Int"},{"issue":"13","key":"2308_CR8","first-page":"1203","volume":"120","author":"C Rapezzi","year":"2009","unstructured":"Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic Cardiac Amyloidoses Circulation. 2009;120(13):1203\u201312.","journal-title":"Systemic Cardiac Amyloidoses Circulation"},{"issue":"45","key":"2308_CR9","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","volume":"40","author":"M Emdin","year":"2019","unstructured":"Emdin M, Aimo A, Rapezzi C, Fontana M, Perfetto F, Seferovi\u0107 PM, et al. Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J. 2019;40(45):3699\u2013706.","journal-title":"Eur Heart J"},{"key":"2308_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejim.2020.05.015","volume":"80","author":"A Aimo","year":"2020","unstructured":"Aimo A, Vergaro G, Castiglione V, Rapezzi C, Emdin M. Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis. Eur J Intern Med. 2020;80:66\u201372.","journal-title":"Eur J Intern Med"},{"issue":"4","key":"2308_CR11","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1002\/ehf2.13411","volume":"8","author":"G Tini","year":"2021","unstructured":"Tini G, Cappelli F, Biagini E, Musumeci B, Merlo M, Crotti L, et al. Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey. ESC Heart Fail. 2021;8(4):3369\u201374.","journal-title":"ESC Heart Fail"},{"issue":"sup1","key":"2308_CR12","first-page":"132","volume":"24","author":"F Aus dem Siepen","year":"2017","unstructured":"Aus dem Siepen F, Hein S, Bauer R, Katus HA, Kristen AV. Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful? Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2017;24(sup1):132\u20133.","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"issue":"24","key":"2308_CR13","doi-asserted-by":"publisher","first-page":"e022859","DOI":"10.1161\/JAHA.121.022859","volume":"10","author":"RK Cheng","year":"2021","unstructured":"Cheng RK, Vasbinder A, Levy WC, Goyal P, Griffin JM, Leedy DJ, et al. Lack of association between neurohormonal Blockade and survival in transthyretin cardiac amyloidosis. J Am Heart Assoc. 2021;10(24):e022859.","journal-title":"J Am Heart Assoc"},{"issue":"13","key":"2308_CR14","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","volume":"79","author":"C Rapezzi","year":"2022","unstructured":"Rapezzi C, Aimo A, Serenelli M, Barison A, Vergaro G, Passino C, et al. Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC State-of-the-Art review. J Am Coll Cardiol. 2022;79(13):1288\u2013303.","journal-title":"J Am Coll Cardiol"},{"key":"2308_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejim.2024.01.001","volume":"123","author":"A Porcari","year":"2024","unstructured":"Porcari A, Sinagra G, Gillmore JD, Fontana M, Hawkins PN. Breakthrough advances enhancing care in ATTR amyloid cardiomyopathy. Eur J Intern Med. 2024;123:29\u201336.","journal-title":"Eur J Intern Med"},{"issue":"4","key":"2308_CR16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jaccao.2022.07.007","volume":"4","author":"E Gonzalez-Lopez","year":"2022","unstructured":"Gonzalez-Lopez E, Escobar-Lopez L, Obici L, Saturi G, Bezard M, Saith SE, et al. Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms. JACC CardioOncol. 2022;4(4):442\u201354.","journal-title":"JACC CardioOncol"},{"issue":"31","key":"2308_CR17","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","volume":"44","author":"A Ioannou","year":"2023","unstructured":"Ioannou A, Massa P, Patel RK, Razvi Y, Porcari A, Rauf MU, et al. Conventional heart failure therapy in cardiac ATTR amyloidosis. Eur Heart J. 2023;44(31):2893\u2013907.","journal-title":"Eur Heart J"},{"issue":"4","key":"2308_CR18","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/ejhf.3245","volume":"26","author":"A Porcari","year":"2024","unstructured":"Porcari A, Fontana M. The changing landscape of heart failure treatment in transthyretin amyloid cardiomyopathy: is the time ripe for clinical use of sodium\u2013glucose cotransporter 2 inhibitors? Eur J Heart Fail. 2024;26(4):948\u201351.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"2308_CR19","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/ejhf.2533","volume":"24","author":"A Porcari","year":"2022","unstructured":"Porcari A, Rossi M, Cappelli F, Canepa M, Musumeci B, Cipriani A, et al. Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis. Eur J Heart Fail. 2022;24(7):1227\u201336.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2308_CR20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ehf2.14188","volume":"10","author":"S Dobner","year":"2023","unstructured":"Dobner S, Bernhard B, Asatryan B, Windecker S, Stortecky S, Pilgrim T, et al. SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin. ESC Heart Fail. 2023;10(1):397\u2013404.","journal-title":"ESC Heart Fail"},{"issue":"24","key":"2308_CR21","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","volume":"83","author":"A Porcari","year":"2024","unstructured":"Porcari A, Cappelli F, Nitsche C, Tomasoni D, Sinigiani G, Longhi S, et al. SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2024;83(24):2411\u201322.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"2308_CR22","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/ejhf.3198","volume":"26","author":"FM Lang","year":"2024","unstructured":"Lang FM, Teruya S, Weinsaft A, Cuomo M, Santos AM, Nalbandian A, et al. Sodium\u2013glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety. Eur J Heart Fail. 2024;26(4):938\u201347.","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"2308_CR23","doi-asserted-by":"publisher","first-page":"101509","DOI":"10.1016\/j.cpcardiol.2022.101509","volume":"48","author":"JA Kim","year":"2023","unstructured":"Kim JA, Wu L, Rodriguez M, Lentine KL, Virk HUH, Hachem K, El, et al. Recent developments in the evaluation and management of cardiorenal syndrome: A comprehensive review. Curr Probl Cardiol. 2023;48(3):101509.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"2308_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/ejhf.3094","volume":"26","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, Rauf MU, Patel RK, Razvi Y, Porcari A, Martinez-Naharro A, et al. Albuminuria in transthyretin cardiac amyloidosis: prevalence, progression and prognostic importance. Eur J Heart Fail. 2024;26(1):65\u201373.","journal-title":"Eur J Heart Fail"},{"key":"2308_CR25","doi-asserted-by":"crossref","unstructured":"Rauf MU, Law S, Santostefano M, Hawkins PN, Petrie A, Cappelli F et al. Revised renal stratification and progression models for predicting long-term renal outcomes in immunoglobulin light chain amyloidosis. Haematologica. 2025 Available from: https:\/\/haematologica.org\/article\/view\/12139","DOI":"10.3324\/haematol.2025.287703"},{"issue":"9","key":"2308_CR26","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1093\/ndt\/gfad006","volume":"38","author":"J Dang","year":"2023","unstructured":"Dang J, Ferlicot S, Misrahi M, Mussini C, Kounis I, R\u00e9my P, et al. Pathological spectrum of hereditary transthyretin renal amyloidosis and clinicopathologic correlation: a French observational study. Nephrol Dial Transplant. 2023;38(9):2019\u201330.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"2308_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jaccao.2024.03.004","volume":"6","author":"L Obici","year":"2024","unstructured":"Obici L, Mussinelli R, Palladini G. Learn Trials JACC CardioOncology. 2024;6(2):307\u20139.","journal-title":"Learn Trials JACC CardioOncology"},{"key":"2308_CR28","doi-asserted-by":"crossref","unstructured":"Ferraro PM, D\u2019Ambrosio V, Di Paolantonio A, Guglielmino V, Calabresi P, Sabatelli M et al. Renal involvement in hereditary transthyretin amyloidosis: an Italian Single-Centre experience. Brain Sci. 2021;11(8).","DOI":"10.3390\/brainsci11080980"},{"issue":"9","key":"2308_CR29","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/ckj\/sfac118","volume":"15","author":"J Solignac","year":"2022","unstructured":"Solignac J, Delmont E, Fortanier E, Attarian S, Mancini J, Daniel L, et al. Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients. Clin Kidney J. 2022;15(9):1747\u201354.","journal-title":"Clin Kidney J"},{"issue":"30","key":"2308_CR30","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799\u2013806.","journal-title":"Eur Heart J"},{"issue":"9","key":"2308_CR31","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/ejhf.3354","volume":"26","author":"C Nitsche","year":"2024","unstructured":"Nitsche C, Ioannou A, Patel RK, Razvi Y, Porcari A, Rauf MU, et al. Expansion of the National amyloidosis centre staging system to detect early mortality in transthyretin cardiac amyloidosis. Eur J Heart Fail. 2024;26(9):2008\u201312.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"2308_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamacardio.2024.4578","volume":"10","author":"A Ioannou","year":"2025","unstructured":"Ioannou A, Razvi Y, Porcari A, Rauf MU, Martinez-Naharro A, Venneri L, et al. Kidney Outcomes in Transthyretin Amyloid Cardiomyopathy. JAMA Cardiol. 2025;10(1):50. https:\/\/doi.org\/10.1001\/jamacardio.2024.4578.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"2308_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jaccao.2024.02.007","volume":"6","author":"BW Sperry","year":"2024","unstructured":"Sperry BW, Sultan MB, Gundapaneni B, Tai SS, Witteles RM. Effect of Tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT. JACC CardioOncol. 2024;6(2):300\u20136.","journal-title":"JACC CardioOncol"},{"issue":"6","key":"2308_CR34","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/j.ekir.2025.03.029","volume":"10","author":"J Dang","year":"2025","unstructured":"Dang J, Solignac J, Ferlicot S, Mussini C, Bridoux F, Huart A, et al. Kidney outcomes in patients with hereditary transthyretin amyloid nephropathy treated with transthyretin stabilizers and gene-silencer therapies. Kidney Int Rep. 2025;10(6):1939\u201349.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2308_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12872-023-03140-y","volume":"23","author":"R Hassan","year":"2023","unstructured":"Hassan R, Miller RJH, Howlett JG, White JA, Fine NM. Prevalence, incidence and clinical outcomes of epicardial coronary artery disease among transthyretin amyloidosis cardiomyopathy patients. BMC Cardiovasc Disord. 2023;23(1):124.","journal-title":"BMC Cardiovasc Disord"},{"key":"2308_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2023.131204","volume":"389","author":"L De Michieli","year":"2023","unstructured":"De Michieli L, De Gaspari M, Sinigiani G, Lupi A, Vedovelli L, Salvalaggio A, et al. Chest pain in cardiac amyloidosis: occurrence, causes and prognostic significance. Int J Cardiol. 2023;389:131204.","journal-title":"Int J Cardiol"},{"issue":"4","key":"2308_CR37","first-page":"358","volume":"2","author":"S Dorbala","year":"2014","unstructured":"Dorbala S, Vangala D, Bruyere JJ, Quarta C, Kruger J, Padera R, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC: Heart Failure. 2014;2(4):358\u201367.","journal-title":"JACC: Heart Failure"},{"issue":"2","key":"2308_CR38","first-page":"113","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC: Heart Failure. 2014;2(2):113\u201322.","journal-title":"JACC: Heart Failure"},{"issue":"3","key":"2308_CR39","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ejhf.3137","volume":"26","author":"L Chacko","year":"2024","unstructured":"Chacko L, Kotecha T, Ioannou A, Patel N, Martinez-Naharro A, Razvi Y, et al. Myocardial perfusion in cardiac amyloidosis. Eur J Heart Fail. 2024;26(3):598\u2013609.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"2308_CR40","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s10741-021-10210-w","volume":"27","author":"MM Uddin","year":"2022","unstructured":"Uddin MM, Mir T, Kaur J, Pervaiz E, Babu MA, Sheikh M. ST-elevation myocardial infarction among cardiac amyloidosis patients; a national readmission database study. Heart Fail Rev. 2022;27(5):1579\u201386.","journal-title":"Heart Fail Rev"},{"key":"2308_CR41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ahj.2024.11.004","volume":"280","author":"N Noory","year":"2025","unstructured":"Noory N, Westin O, Maurer MS, Fosb\u00f8l E, Gustafsson F. Chest pain and coronary artery disease in cardiac amyloidosis: prevalence, mechanisms, and clinical implications. Am Heart J. 2025;280:52\u20139.","journal-title":"Am Heart J"},{"issue":"4","key":"2308_CR42","first-page":"351","volume":"6","author":"S Giancaterino","year":"2020","unstructured":"Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. JACC: Clinical Electrophysiology. 2020;6(4):351\u201361.","journal-title":"JACC: Clinical Electrophysiology"},{"issue":"3","key":"2308_CR43","first-page":"147","volume":"22","author":"S Longhi","year":"2015","unstructured":"Longhi S, Quarta CC, Milandri A, Lorenzini M, Gagliardi C, Manuzzi L, et al. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2015;22(3):147\u201355.","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis"},{"key":"2308_CR44","doi-asserted-by":"publisher","first-page":"131346","DOI":"10.1016\/j.ijcard.2023.131346","volume":"392","author":"C Fumagalli","year":"2023","unstructured":"Fumagalli C, Zampieri M, Argir\u00f2 A, Tassetti L, Rossi G, Musumeci B, et al. Incidence and determinants of atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosis. Int J Cardiol. 2023;392:131346.","journal-title":"Int J Cardiol"},{"key":"2308_CR45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.amjcard.2025.06.015","volume":"254","author":"JK Skov","year":"2025","unstructured":"Skov JK, Ladefoged B, Pedersen ALD, Clemmensen TS, Nielsen JC, Poulsen SH. Atrial fibrillation Burden, risk Factors, and prognosis in Wild-type transthyretin amyloidosis cardiomyopathy. Am J Cardiol. 2025;254:85\u201393.","journal-title":"Am J Cardiol"},{"issue":"4","key":"2308_CR46","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jaccao.2024.03.007","volume":"6","author":"R Witteles","year":"2024","unstructured":"Witteles R, Jefferies JL, Kapa S, Cappelli F, Sultan MB, Gundapaneni B, et al. Atrial fibrillation as a prognostic factor for all-cause mortality in patients with transthyretin amyloid cardiomyopathy. JACC CardioOncol. 2024;6(4):592\u20138.","journal-title":"JACC CardioOncol"},{"issue":"9","key":"2308_CR47","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","volume":"6","author":"E Donnellan","year":"2020","unstructured":"Donnellan E, Wazni OM, Hanna M, Elshazly MB, Puri R, Saliba W, et al. Atrial fibrillation in transthyretin cardiac amyloidosis: Predictors, Prevalence, and efficacy of rhythm control strategies. JACC Clin Electrophysiol. 2020;6(9):1118\u201327.","journal-title":"JACC Clin Electrophysiol"},{"key":"2308_CR48","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.amjcard.2020.07.034","volume":"133","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Sperry BW, Gabrovsek A, Ikram A, Tang WHW, Estep J, et al. Digoxin use in cardiac amyloidosis. Am J Cardiol. 2020;133:134\u20138.","journal-title":"Am J Cardiol"},{"key":"2308_CR49","doi-asserted-by":"publisher","first-page":"33","DOI":"10.20517\/2574-1209.2021.134","volume":"6","author":"A Porcari","year":"2022","unstructured":"Porcari A, Pagura L, Varr\u00e0 GG, Rossi M, Longo F, Saro R, et al. Grey zones in the supportive treatments of cardiac amyloidosis. Vessel Plus. 2022;6:33.","journal-title":"Vessel Plus"},{"issue":"5","key":"2308_CR50","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","volume":"73","author":"EA El-Am","year":"2019","unstructured":"El-Am EA, Dispenzieri A, Melduni RM, Ammash NM, White RD, Hodge DO, et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol. 2019;73(5):589\u201397.","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"2308_CR51","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","volume":"73","author":"A Martinez-Naharro","year":"2019","unstructured":"Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, Mirelis JG, Baksi AJ, Moon JC, et al. High prevalence of intracardiac thrombi in cardiac amyloidosis. J Am Coll Cardiol. 2019;73(13):1733\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"2308_CR52","doi-asserted-by":"crossref","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ et al. Cardiac amyloidosis: evolving diagnosis and management: A scientific statement from the American heart association. Circulation 2020;142(1).","DOI":"10.1161\/CIR.0000000000000792"},{"key":"2308_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.01.002","author":"RS Loungani","year":"2020","unstructured":"Loungani RS, Rehorn MR, Geurink KR, Coniglio AC, Black-Maier E, Pokorney SD, et al. Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter. Am Heart J. 2020. https:\/\/doi.org\/10.1016\/j.ahj.2020.01.002.","journal-title":"Am Heart J"},{"issue":"10","key":"2308_CR54","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/jce.13046","volume":"27","author":"NY Tan","year":"2016","unstructured":"Tan NY, Mohsin Y, Hodge DO, Lacy MQ, Packer DL, Dispenzieri A, et al. Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol. 2016;27(10):1167\u201373.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2308_CR55","doi-asserted-by":"crossref","unstructured":"Girvin ZP, Sweat AO, Kochav SM, Maurer MS, Dizon J, Wan EY, et al. Tafamidis and incidence of atrial fibrillation in transthyretin amyloid Cardiomyopathy, JACC. Clinical electrophysiology; 2023. pp. 586\u20137.","DOI":"10.1016\/j.jacep.2022.11.005"},{"issue":"37","key":"2308_CR56","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R, Basso C, et al. 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J. 2023;44(37):3503\u2013626.","journal-title":"Eur Heart J"},{"issue":"8","key":"2308_CR57","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/ejhf.2566","volume":"24","author":"S Vilches","year":"2022","unstructured":"Vilches S, Fontana M, Gonzalez-Lopez E, Mitrani L, Saturi G, Renju M, et al. Systemic embolism in amyloid transthyretin cardiomyopathy. Eur J Heart Fail. 2022;24(8):1387\u201396.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"2308_CR58","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jcmg.2025.04.007","volume":"18","author":"B Ozbay","year":"2025","unstructured":"Ozbay B, Rearick C, Satyavolu BS, Soman P, Wong TC, Starr M, et al. Primary left atrial cardiopathy in transthyretin amyloidosis cardiomyopathy by multimodality imaging. JACC Cardiovasc Imaging. 2025;18(8):867\u201381.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"9","key":"2308_CR59","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/ejhf.2648","volume":"24","author":"A Porcari","year":"2022","unstructured":"Porcari A, Merlo M, Sinagra G. Time to reconsider thromboembolic risk and anticoagulation in transthyretin cardiac amyloidosis? Eur J Heart Fail. 2022;24(9):1716\u20138.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"2308_CR60","first-page":"251","volume":"26","author":"A Lalario","year":"2025","unstructured":"Lalario A, Fabris E, Rakar S, Massa L, Benussi A, Sinagra G. [Cerebral amyloid angiopathy and left atrial appendage occlusion: evidence and possible management for a collaborative approach between cardiology and neurology]. G Ital Cardiol (Rome). 2025;26(4):251\u201360.","journal-title":"G Ital Cardiol (Rome)"},{"issue":"7","key":"2308_CR61","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.rec.2022.08.001","volume":"76","author":"IJ Amat-Santos","year":"2023","unstructured":"Amat-Santos IJ, Delgado-Arana JR, Cruz-Gonz\u00e1lez I, Guti\u00e9rrez H, Garc\u00eda-Bolao I, Mill\u00e1n X, et al. Cardiac amyloidosis and left atrial appendage closure. The CAMYLAAC study. Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition). 2023;76(7):503\u201310.","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"key":"2308_CR62","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.amjcard.2020.05.021","volume":"128","author":"E Donnellan","year":"2020","unstructured":"Donnellan E, Wazni OM, Saliba WI, Hanna M, Kanj M, Patel DR, et al. Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis. Am J Cardiol. 2020;128:140\u20136.","journal-title":"Am J Cardiol"},{"issue":"1","key":"2308_CR63","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/heartjnl-2022-322315","volume":"110","author":"G Saturi","year":"2023","unstructured":"Saturi G, De Frutos F, Sguazzotti M, Gonzalez-Lopez E, Nardi E, Dom\u00ednguez F, et al. Predictors and outcomes of pacemaker implantation in patients with cardiac amyloidosis. Heart. 2023;110(1):40\u20138.","journal-title":"Heart"},{"issue":"11","key":"2308_CR64","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1111\/jce.14180","volume":"30","author":"E Donnellan","year":"2019","unstructured":"Donnellan E, Wazni OM, Saliba WI, Baranowski B, Hanna M, Martyn M, et al. Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol. 2019;30(11):2427\u201332.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"2","key":"2308_CR65","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.rec.2021.08.016","volume":"75","author":"FJ Berm\u00fadez-Jim\u00e9nez","year":"2022","unstructured":"Berm\u00fadez-Jim\u00e9nez FJ, Molina-Lerma M, Mac\u00edas-Ruiz R, S\u00e1nchez-Mill\u00e1n P, Jim\u00e9nez-J\u00e1imez J, \u00c1lvarez M. Initial experience with left bundle branch area pacing in patients with transthyretin cardiac amyloidosis. Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition). 2022;75(2):182\u20134.","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"issue":"1","key":"2308_CR66","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","volume":"11","author":"BC Varr","year":"2014","unstructured":"Varr BC, Zarafshar S, Coakley T, Liedtke M, Lafayette RA, Arai S, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm. 2014;11(1):158\u201362.","journal-title":"Heart Rhythm"},{"issue":"5","key":"2308_CR67","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jjcc.2023.02.009","volume":"81","author":"S Bukhari","year":"2023","unstructured":"Bukhari S, Khan B. Prevalence of ventricular arrhythmias and role of implantable cardioverter-defibrillator in cardiac amyloidosis. J Cardiol. 2023;81(5):429\u201333.","journal-title":"J Cardiol"},{"issue":"3","key":"2308_CR68","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/13506129.2022.2060073","volume":"29","author":"F Cappelli","year":"2022","unstructured":"Cappelli F, Cipriani A, Russo D, Tini G, Zampieri M, Zocchi C, et al. Prevalence and prognostic role of nonsustained ventricular tachycardia in cardiac amyloidosis. Amyloid. 2022;29(3):211\u20132.","journal-title":"Amyloid"},{"issue":"11","key":"2308_CR69","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","volume":"81","author":"MM Kittleson","year":"2023","unstructured":"Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, Clarke JO, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: A report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2023;81(11):1076\u2013126.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"2308_CR70","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","volume":"74","author":"J Ternacle","year":"2019","unstructured":"Ternacle J, Krapf L, Mohty D, Magne J, Nguyen A, Galat A, et al. Aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol. 2019;74(21):2638\u201351.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2308_CR71","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","volume":"77","author":"C Nitsche","year":"2021","unstructured":"Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J Am Coll Cardiol. 2021;77(2):128\u201339.","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"2308_CR72","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/eurheartj\/ehz905","volume":"41","author":"L Chacko","year":"2020","unstructured":"Chacko L, Martone R, Bandera F, Lane T, Martinez-Naharro A, Boldrini M, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. Eur Heart J. 2020;41(14):1439\u201347.","journal-title":"Eur Heart J"},{"key":"2308_CR73","doi-asserted-by":"publisher","unstructured":"Nitsche C, Dobner S, Rosenblum HR, Patel KP, Longhi S, Yilmaz A et al. Cardiac transthyretin amyloidosis treatment improves outcomes after aortic valve replacement for severe stenosis. Eur Heart J 2025:ehaf362. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf362","DOI":"10.1093\/eurheartj\/ehaf362"},{"issue":"17","key":"2308_CR74","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1016\/j.jcin.2022.06.009","volume":"15","author":"C Don\u00e0","year":"2022","unstructured":"Don\u00e0 C, Nitsche C, Koschutnik M, Heitzinger G, Mascherbauer K, Kammerlander AA, et al. Unveiling cardiac amyloidosis, its characteristics, and outcomes among patients with MR undergoing transcatheter edge-to-edge MV repair. JACC Cardiovasc Interv. 2022;15(17):1748\u201358.","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"2308_CR75","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10741-023-10350-1","volume":"29","author":"A Aimo","year":"2024","unstructured":"Aimo A, Camerini L, Fabiani I, Morfino P, Panichella G, Barison A, et al. Valvular heart disease in patients with cardiac amyloidosis. Heart Fail Rev. 2024;29(1):65\u201377.","journal-title":"Heart Fail Rev"},{"issue":"9","key":"2308_CR76","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/ejhf.2606","volume":"24","author":"L Chacko","year":"2022","unstructured":"Chacko L, Karia N, Venneri L, Bandera F, Passo BD, Buonamici L, et al. Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis. Eur J Heart Fail. 2022;24(9):1700\u201312.","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"2308_CR77","first-page":"1007","volume":"25","author":"D Tomasoni","year":"2024","unstructured":"Tomasoni D, Aimo A, Porcari A, Bonfioli GB, Castiglione V, Saro R, et al. Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis. Eur Heart J. 2024;25(7):1007\u201317.","journal-title":"Eur Heart J"},{"key":"2308_CR78","doi-asserted-by":"publisher","first-page":"1085824","DOI":"10.3389\/fcvm.2023.1085824","volume":"10","author":"S Matteo","year":"2023","unstructured":"Matteo S, Anna C, Federico S, Daniele M, Gioele F, Beatrice DP, et al. Stroke volume and myocardial contraction fraction in transthyretin amyloidosis cardiomyopathy: A systematic review. Front Cardiovasc Med. 2023;10:1085824.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"2308_CR79","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ejhf.2776","volume":"25","author":"A Porcari","year":"2023","unstructured":"Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU, et al. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2023;25(4):515\u201324.","journal-title":"Eur J Heart Fail"},{"key":"2308_CR80","doi-asserted-by":"publisher","DOI":"10.1093\/ehjqcco\/qcaf024\/8139085","author":"C Fumagalli","year":"2025","unstructured":"Fumagalli C, Longhi S, Aimo A, Argir\u00f2 A, Barilaro A, Biagini E, et al. Change in prevalence of ATTR variants in italy: results from a National survey. Eur Hear J - Qual Care Clin Outcomes. 2025. https:\/\/doi.org\/10.1093\/ehjqcco\/qcaf024\/8139085.","journal-title":"Eur Hear J - Qual Care Clin Outcomes"},{"issue":"3","key":"2308_CR81","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/jns.12403","volume":"25","author":"F Wajnsztajn Yungher","year":"2020","unstructured":"Wajnsztajn Yungher F, Kim A, Boehme A, Kleyman I, Weimer LH, Maurer MS, et al. Peripheral neuropathy symptoms in wild type transthyretin amyloidosis. J Peripher Nerv Syst. 2020;25(3):265\u201372.","journal-title":"J Peripher Nerv Syst"},{"key":"2308_CR82","doi-asserted-by":"publisher","first-page":"1242815","DOI":"10.3389\/fneur.2023.1242815","volume":"14","author":"L Poli","year":"2023","unstructured":"Poli L, Labella B, Cotti Piccinelli S, Caria F, Risi B, Damioli S, et al. Hereditary transthyretin amyloidosis: a comprehensive review with a focus on peripheral neuropathy. Front Neurol. 2023;14:1242815.","journal-title":"Front Neurol"},{"key":"2308_CR83","doi-asserted-by":"publisher","first-page":"1345608","DOI":"10.3389\/fcvm.2024.1345608","volume":"11","author":"SA \u017divkovi\u0107","year":"2024","unstructured":"\u017divkovi\u0107 SA, Lacomis D, Soman P. Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center\u2019s experience. Front Cardiovasc Med. 2024;11:1345608.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"2308_CR84","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3109\/13506129809007303","volume":"5","author":"Y Ando","year":"1998","unstructured":"Ando Y, Suhr OB. Autonomic dysfunction in familial amyloidotic polyneuropathy (FAP). Amyloid. 1998;5(4):288\u2013300.","journal-title":"Amyloid"},{"issue":"3","key":"2308_CR85","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jaccao.2025.01.018","volume":"7","author":"C Fumagalli","year":"2025","unstructured":"Fumagalli C, Ioannou A, Cappelli F, Maurer MS, Razvi Y, Porcari A, et al. Clinical phenotype and prognostic significance of frailty in transthyretin cardiac amyloidosis. JACC CardioOncol. 2025;7(3):268\u201378.","journal-title":"JACC CardioOncol"},{"issue":"9","key":"2308_CR86","doi-asserted-by":"publisher","first-page":"101123","DOI":"10.1016\/j.jacadv.2024.101123","volume":"3","author":"C Fumagalli","year":"2024","unstructured":"Fumagalli C, Maurer MS, Fontana M, Fine N, Gillmore J, Goyal P, et al. Comprehensive geriatric assessment to optimize the management of older patients with transthyretin cardiac amyloidosis. JACC Adv. 2024;3(9):101123.","journal-title":"JACC Adv"},{"issue":"1","key":"2308_CR87","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1186\/s12877-022-03404-w","volume":"22","author":"Y Peng","year":"2022","unstructured":"Peng Y, Zhong G-C, Zhou X, Guan L, Zhou L. Frailty and risks of all-cause and cause-specific death in community-dwelling adults: a systematic review and meta-analysis. BMC Geriatr. 2022;22(1):725.","journal-title":"BMC Geriatr"},{"issue":"9868","key":"2308_CR88","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","volume":"381","author":"A Clegg","year":"2013","unstructured":"Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752\u201362.","journal-title":"Lancet"},{"issue":"3","key":"2308_CR89","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.hfc.2024.03.005","volume":"20","author":"R Saro","year":"2024","unstructured":"Saro R, Allegro V, Merlo M, Dore F, Sinagra G, Porcari A. Specific therapy in transthyretin amyloid cardiomyopathy: future perspectives beyond tafamidis. Heart Fail Clin. 2024;20(3):343\u201352.","journal-title":"Heart Fail Clin"},{"issue":"8","key":"2308_CR90","doi-asserted-by":"publisher","first-page":"102549","DOI":"10.1016\/j.jchf.2025.102549","volume":"13","author":"G Sinigiani","year":"2025","unstructured":"Sinigiani G, Sanna GD, Aimo A, Porcari A, Bonacchi G, De Michieli L, et al. Outcome and disease progression in NYHA functional class I and II patients with Wild-Type transthyretin cardiomyopathy treated with Tafamidis. JACC Hear Fail. 2025;13(8):102549.","journal-title":"JACC Hear Fail"},{"issue":"4","key":"2308_CR91","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1001\/jamacardio.2024.0022","volume":"9","author":"RK Patel","year":"2024","unstructured":"Patel RK, Bandera F, Venneri L, Porcari A, Razvi Y, Ioannou A, et al. Cardiopulmonary exercise testing in evaluating transthyretin amyloidosis. JAMA Cardiol. 2024;9(4):367\u201376.","journal-title":"JAMA Cardiol"},{"issue":"Supplement2","key":"2308_CR92","doi-asserted-by":"publisher","first-page":"ehaa9462115","DOI":"10.1093\/ehjci\/ehaa946.2115","volume":"41","author":"C Rapezzi","year":"2020","unstructured":"Rapezzi C, Kristen AV, Gundapaneni B, Sultan MB, Hanna M. Benefits of Tafamidis in patients with advanced transthyretin amyloid cardiomyopathy. Eur Heart J. 2020;41(Supplement2):ehaa9462115.","journal-title":"Eur Heart J"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02308-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-025-02308-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-025-02308-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T09:04:46Z","timestamp":1772096686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-025-02308-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,25]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2308"],"URL":"https:\/\/doi.org\/10.1007\/s11886-025-02308-6","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,25]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No animal or human subjects by the authors were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}